| Schallenkamp, John M. |
Montana Cancer Consortium
United States |
Montana Cancer Consortium: An Inclusive and Collaborative Approach to Clinical Trial Accrual and Cancer Care Delivery Research across Montana, Idaho and Wyoming |
5UG1CA189872-10 |
|
Brandy Heckman-Stoddard, Ph.D., M.P.H. |
| Doolittle, Gary C. |
University Of Kansas Medical Center
United States |
The University of Kansas Cancer Center's- MCA Rural NCORP |
5UG1CA239767-05 |
|
Brandy Heckman-Stoddard, Ph.D., M.P.H. |
| Marshall, David T. |
Medical University Of South Carolina
United States |
Medical University of South Carolina NCORP Minority/Underserved Community Site |
5UG1CA189848-10 |
|
Brandy Heckman-Stoddard, Ph.D., M.P.H. |
| Wang, Tza-Huei Jeff |
Johns Hopkins University
United States |
A low-cost, multiplexed digital high resolution melt platform for DNA methylation-based detection and identification of cancers in liquid biopsies |
5R33CA272321-02 |
|
|
| Tollefsbol, Trygve O |
University Of Alabama At Birmingham
United States |
Combinatorial epigenetic-based prevention of breast cancer |
5R01CA178441-09 |
|
|
| Dhakal, Soma |
Virginia Commonwealth University
United States |
Single-Molecule High-Confidence Detection of miRNA Cancer Biomarkers |
5R61CA278445-02 |
|
|
| Augenlicht, Leonard H |
Albert Einstein College Of Medicine
United States |
A Major Nutritional Effect on Intestinal Stem Cells and Tumors |
5R01CA214625-06 |
|
Nancy J. Emenaker, Ph.D., R.D.N., L.D., F.A.N.D. |
| Kong, Mei |
University Of California-Irvine
United States |
Using dietary glutamine supplementation for melanoma prevention and targeted therapy |
5R01CA244360-03 |
PA-20-185 (Parent R01 Clinical Trial Not Allowed) |
|
| Hinds, Pamela S |
Children'S Research Institute
United States |
Longitudinal, multimodal assessment of neuropsychological functioning in children diagnosed with high-risk acute lymphoblastic leukemia (HR-ALL): Using early changes to predict later impairment |
5R01CA212190-05 |
|
|
| Ondrey, Frank G. |
University Of Minnesota
United States |
Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia |
5R01CA254270-02 |
PAR-21-035 (R01 Clinical Trial Required) |
|